|Articles|July 1, 2020
- Pharmaceutical Executive-07-01-2020
- Volume 40
- Issue 7
Pharmaceutical Executive, July 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Will COVID-19 Usher in a New Era in Pharma Marketing?almost 6 years ago
Is Drug Production Heading Back to Europe From Abroad?almost 6 years ago
Central Focus: Targeting Unmet Need in CNSalmost 6 years ago
Will the Industry Rise to the Occasion?almost 6 years ago
How Oncologists are Coping with COVID-19almost 6 years ago
Virtual Hiring of the C-Suitealmost 6 years ago
Culture and Compliance: Building a Culture of Business Ethicsalmost 6 years ago
Fauci: Industry Will ‘Walk Away’ From COVID Price Controlsalmost 6 years ago
A Sustainable Response to COVID-19almost 6 years ago
Enterprise Leadership: Is Compliance Ripe for Disruption?Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
5
